Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 Double-Blind Randomized Study of DNL310 vs Idursulfase in MPS II
2021-005200-35Phase 2Active
- Sponsor
- Denali Therapeutics Inc.
- Start
- Apr 2022
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of tividenofusp alfa in mucopolysaccharidosis type 2 (2 arms), sponsored by Denali Therapeutics Inc. Primary endpoint: Percent change from baseline in CSF heparan sulfate concentration at Week 24 (Cohort A). Started Apr 2022; status: active.
02
Drugs
tividenofusp alfa
03
Conditions
mucopolysaccharidosis type 2
Beyond the preview
Go deeper on 2021-005200-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005200-35.